Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Phase 1b Study of ASP1951, a GITR Agonistic Antibody, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
NCT Number:
NCT03799003
Phase:
I
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Larynx, Lip, Oral Cavity and Pharynx, Lung, Melanoma, Skin, Thyroid
Study Objectives:
The primary purpose of this study is to evaluate the tolerability and safety profile of ASP1951 when administered as a single agent and in combination with pembrolizumab in participants with locally advanced (unresectable) or metastatic solid tumors; characterize the pharmacokinetic profile of ASP1951 when administered as a single agent and in combination with pembrolizumab; and determine the recommended phase 2 dose (RP2D) of ASP1951 when administered as a single agent and in combination with pembrolizumab and/or maximum tolerated dose (MTD). This study will also evaluate the anti-tumor effect of ASP1951 when administered as a single agent and in combination with pembrolizumab.
Study Documents
(MUSC NetID required for document access)